ClinicalTrials.gg
CompletedNCT00195676Updated Apr 13, 2011Results posted

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of adalimumab in Psoriasis, sponsored by Abbott. Completed at 104 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-13.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,469
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
Largest of 48
1,469 · median 148
Started
2004
with 1 other
Phase 3
26 of 48
1 open now
Registered
1st of 48
by date
Lead sponsor
11 of 48
Abbott

Among the 48 studies testing adalimumab in Psoriasis, this one has the largest enrollment, is one of 2 that started in 2004, is one of 26 in phase 3, and was the 1st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.

Read the detailed description

Study M03-658 was a continuation study for participants with moderate to severe psoriasis who had participated in a prior psoriasis adalimumab study. Study M03-658 consisted of three sequential treatment periods. The first period was Period O, in which participants received open-label treatment with adalimumab (40 mg every other week or 40 mg every week) for a minimum of 104 weeks and a maximum of 252 weeks. Period O was the only period of the study until May 2008, when the subsequent periods were added via amendment to the protocol. At that time, participants who had achieved satisfactory therapeutic response (a Physician's Global Assessment [PGA] of 0, 1, or 2 [clear, minimal, or mild]) were given the opportunity to discontinue from the study or to continue and participate in the subsequent two periods. The second period was Period W, a maximum of 52 weeks, in which participants with a PGA of 2 (mild) or less were withdrawn from adalimumab treatment (i.e., participants received no treatment) until relapse of their psoriasis occurred (defined as a PGA of 3 [moderate] or worse). The third period was Period R, a 16-week period in which participants were retreated with open-label adalimumab (80 mg initial dose followed by 40 mg every other week). Period O was designed to evaluate the first objective regarding long-term efficacy and safety of adalimumab treatment, and Period R was designed to evaluate the effectiveness of adalimumab retreatment following relapse. Specific subsets of the study population that were identified as the populations of interest were the modified intent-to-treat populations for Period W and Period R, and these are described further in the outcome measures.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
  • Subjects who met the requirements from previous adalimumab psoriasis study participation.

Exclusion criteria

Exclusion Criteria:

  • Subject considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
  • Female subject who was pregnant or breast-feeding or considering becoming pregnant.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,469 participants (actual)

Study arms

  • Other
    Adalimumab

    Drug: adalimumab

Interventions

  • 40 mg every other week or 40 mg every week by subcutaneous injection

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R

    The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

    Time frame: Week 16 of Period R

Other outcomes

  1. Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 60

    The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

    Time frame: Week 60

  2. Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 120

    The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

    Time frame: Week 120

  3. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 60

    Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.

    Time frame: Week 60

  4. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 120

    Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.

    Time frame: Week 120

  5. Time to Relapse in Period W

    Relapse of psoriasis was defined as a Physician's Global Assessment (assessment of overall lesion severity) score of greater than or equal to 3 (3=moderate; 4=severe; 5=very severe).

    Time frame: Period W

  6. Percentage of Period R Modified Intent-to-Treat Participants Who Relapsed in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R

    The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

    Time frame: Week 16 of Period R

  7. Percentage of Period R Modified Intent-to-Treat Participants Who Did Not Relapse in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R

    The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

    Time frame: Week 16 of Period R

07

Results

Posted Nov 19, 2010

Participant flow

Period O - Open-label Treatment
Participant flow — Period O - Open-label Treatment
MilestoneAll Adalimumab Treatment
Started1468
Completed862
Not completed606
Withdrew: Adverse event82
Withdrew: Death6
Withdrew: Lack of efficacy198
Withdrew: Lost to follow-up91
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject147
Withdrew: Administrative reasons2
Withdrew: Other reasons68
Period W (Withdrawal) - No Treatment
Participant flow — Period W (Withdrawal) - No Treatment
MilestoneAll Adalimumab Treatment
Started608
Completed0
Not completed608
Withdrew: Adverse event4
Withdrew: Death2
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject46
Withdrew: Relapse (pga >= 3)397
Withdrew: Period w close-out129
Withdrew: Administrative reasons1
Withdrew: Other reasons18
Period R - Retreatment 16 Weeks
Participant flow — Period R - Retreatment 16 Weeks
MilestoneAll Adalimumab Treatment
Started525
Completed490
Not completed35
Withdrew: Adverse event4
Withdrew: Lack of efficacy5
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject9
Withdrew: Other reasons6

Outcome measures

Other pre-specifiedPercentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 60

The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

Time frame:
Week 60
Reported as:
Number · percentage of participants
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 60
percentage of participantsPeriod O Adalimumab EOW Treatment Population
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 6050.6
Other pre-specifiedPercentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 120

The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

Time frame:
Week 120
Reported as:
Number · percentage of participants
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 120
percentage of participantsPeriod O Adalimumab EOW Treatment Population
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 12046.3
PrimaryPercentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R

The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

Time frame:
Week 16 of Period R
Reported as:
Number · percentage of participants
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R
percentage of participantsPeriod R Modified Intent-to-Treat Population
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R76.5
Other pre-specifiedPercentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 60

Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.

Time frame:
Week 60
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 60
percentage of participantsPeriod O Adalimumab EOW Treatment Population
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 6061.4
Other pre-specifiedPercentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 120

Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.

Time frame:
Week 120
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 120
percentage of participantsPeriod O Adalimumab EOW Treatment Population
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 12057.3
Other pre-specifiedTime to Relapse in Period W

Relapse of psoriasis was defined as a Physician's Global Assessment (assessment of overall lesion severity) score of greater than or equal to 3 (3=moderate; 4=severe; 5=very severe).

Time frame:
Period W
Reported as:
Median · days
Time to Relapse in Period W
daysPeriod W Modified Intent-to-treat Population
Time to Relapse in Period W141 (127 to 146)
Other pre-specifiedPercentage of Period R Modified Intent-to-Treat Participants Who Relapsed in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R

The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

Time frame:
Week 16 of Period R
Reported as:
Number · percentage of participants
Percentage of Period R Modified Intent-to-Treat Participants Who Relapsed in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R
percentage of participantsPeriod R mITT Population Relapsed in Period W
Percentage of Period R Modified Intent-to-Treat Participants Who Relapsed in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R69.1
Other pre-specifiedPercentage of Period R Modified Intent-to-Treat Participants Who Did Not Relapse in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R

The Physician's Global Assessment \[PGA\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.

Time frame:
Week 16 of Period R
Reported as:
Number · percentage of participants
Percentage of Period R Modified Intent-to-Treat Participants Who Did Not Relapse in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R
percentage of participantsPeriod R Modified Intent-to-Treat Not Relapsed in Period W
Percentage of Period R Modified Intent-to-Treat Participants Who Did Not Relapse in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R88.8

Adverse events

Collected over 2,095 days(approximately 5.7 years), including adalimumab exposure in prior studies. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Adalimumab Treatment—189/1,468 (12.9%)1,036/1,468 (70.6%)
Most frequent serious events
Showing 10 of 188
Most frequent serious events
EventAll Adalimumab Treatment
Coronary artery diseaseCardiac disorders10/1468
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/1468
OsteoarthritisMusculoskeletal and connective tissue disorders7/1468
CellulitisInfections and infestations6/1468
Myocardial infarctionCardiac disorders5/1468
PneumoniaInfections and infestations5/1468
NephrolithiasisRenal and urinary disorders5/1468
InjuryInjury, poisoning and procedural complications4/1468
ObesityMetabolism and nutrition disorders4/1468
DepressionPsychiatric disorders4/1468
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAll Adalimumab Treatment
NasopharyngitisInfections and infestations391/1468
Upper respiratory tract infectionInfections and infestations298/1468
HeadacheNervous system disorders164/1468
HypertensionVascular disorders163/1468
ArthralgiaMusculoskeletal and connective tissue disorders156/1468
SinusitisInfections and infestations150/1468
BronchitisInfections and infestations116/1468
InfluenzaInfections and infestations113/1468
Back painMusculoskeletal and connective tissue disorders110/1468
CoughRespiratory, thoracic and mediastinal disorders94/1468

Baseline characteristics

Age Continuous
Age Continuous(years)All Adalimumab Treatment
Mean44.1 ± 12.75
Sex: Female, Male
Sex: Female, Male(Participants)All Adalimumab Treatment
Female470
Male998
Region of Enrollment
Region of Enrollment(participants)All Adalimumab Treatment
United States802
Canada501
Austria34
Belgium15
France45
Switzerland3
Spain20
Poland12
Germany36
08

Study locations

104 sites
  • Site Reference ID/Investigator# 1263
    Birmingham, Alabama 35205, United States
  • Site Reference ID/Investigator# 1259
    Buckner 13075 PI, Alabama 35233, United States
  • Site Reference ID/Investigator# 2427
    Scottsdale, Arizona 85251, United States
  • Site Reference ID/Investigator# 2433
    Tucson, Arizona 85710, United States
  • Site Reference ID/Investigator# 100
    Little Rock, Arkansas 72205, United States
  • Site Reference ID/Investigator# 1798
    Bakersfield, California 93309, United States
  • Site Reference ID/Investigator# 122
    Fresno, California 93720, United States
  • Site Reference ID/Investigator# 1669
    Irvine, California 92697, United States
  • Site Reference ID/Investigator# 1285
    Oceanside, California 92056, United States
  • Site Reference ID/Investigator# 86
    San Diego, California 92123, United States
  • Site Reference ID/Investigator# 1679
    Santa Monica, California 90404, United States
  • Site Reference ID/Investigator# 1677
    Torrance, California 90503, United States
  • Site Reference ID/Investigator# 1269
    Longmont, Colorado 80501, United States
  • Site Reference ID/Investigator# 1275
    New Haven, Connecticut 06511, United States
  • Site Reference ID/Investigator# 96
    Jacksonville, Florida 32204, United States
  • Site Reference ID/Investigator# 2431
    Pinellas Park, Florida 33781, United States
  • Site Reference ID/Investigator# 1273
    South Miami, Florida 33143, United States
  • Site Reference ID/Investigator# 2432
    West Palm Beach, Florida 33407, United States
  • Site Reference ID/Investigator# 98
    Alpharetta, Georgia 30022, United States
  • Site Reference ID/Investigator# 1674
    Newnan, Georgia 30263, United States
  • Site Reference ID/Investigator# 1670
    Snellville, Georgia 30078, United States
  • Site Reference ID/Investigator# 1264
    Chicago, Illinois 60612, United States
  • Site Reference ID/Investigator# 1801
    Maywood, Illinois 60153, United States
  • Site Reference ID/Investigator# 1681
    Springfield, Illinois 62702, United States
  • Site Reference ID/Investigator# 1267
    Indianapolis, Indiana 46256, United States
  • Site Reference ID/Investigator# 1671
    Indianapolis, Indiana 46260, United States
  • Site Reference ID/Investigator# 1258
    Louisville, Kentucky 40202, United States
  • Site Reference ID/Investigator# 1281
    Shreveport, Louisiana 71103, United States
  • Site Reference ID/Investigator# 1668
    Andover, Massachusetts 01810, United States
  • Site Reference ID/Investigator# 1683
    Boston, Massachusetts 02114, United States
  • Site Reference ID/Investigator# 83
    Worcester, Massachusetts 01610, United States
  • Site Reference ID/Investigator# 93
    Ann Arbor, Michigan 48109, United States
  • Site Reference ID/Investigator# 92
    Fridley, Minnesota 55432, United States
  • Site Reference ID/Investigator# 1262
    Minneapolis, Minnesota 55455, United States
  • Site Reference ID/Investigator# 1657
    St. Louis, Missouri 63110, United States
  • Site Reference ID/Investigator# 89
    St. Louis, Missouri 63117, United States
  • Site Reference ID/Investigator# 1673
    Omaha, Nebraska 68131, United States
  • Site Reference ID/Investigator# 2119
    New Brunswick, New Jersey 08903, United States
  • Site Reference ID/Investigator# 1672
    New York, New York 10016, United States
  • Site Reference ID/Investigator# 1797
    New York, New York 10025, United States
  • Site Reference ID/Investigator# 95
    New York, New York 10029, United States
  • Site Reference ID/Investigator# 1655
    New York, New York 10032, United States
  • Site Reference ID/Investigator# 88
    Rochester, New York 14623, United States
  • Site Reference ID/Investigator# 1256
    Williamsville, New York 14221, United States
  • Site Reference ID/Investigator# 1266
    Raleigh, North Carolina 27612, United States
  • Site Reference ID/Investigator# 1265
    Cincinnati, Ohio 45219, United States
  • Site Reference ID/Investigator# 90
    Cleveland, Ohio 44106, United States
  • Site Reference ID/Investigator# 2434
    Columbus, Ohio 43212, United States
  • Site Reference ID/Investigator# 1260
    Lake Oswego, Oregon 97035, United States
  • Site Reference ID/Investigator# 1667
    Portland, Oregon 97210, United States
  • Site Reference ID/Investigator# 121
    Portland, Oregon 97223, United States
  • Site Reference ID/Investigator# 1323
    Hershey, Pennsylvania 17033, United States
  • Site Reference ID/Investigator# 1277
    Philadelphia, Pennsylvania 19103, United States
  • Site Reference ID/Investigator# 99
    Johnston, Rhode Island 02919, United States
  • Site Reference ID/Investigator# 1676
    Providence, Rhode Island 02903, United States
  • Site Reference ID/Investigator# 97
    Greer, South Carolina 29651, United States
  • Site Reference ID/Investigator# 5199
    Mount Pleasant, South Carolina 29464, United States
  • Site Reference ID/Investigator# 1800
    Goodlettsville, Tennessee 37072, United States
  • Site Reference ID/Investigator# 1282
    Nashville, Tennessee 37215, United States
  • Site Reference ID/Investigator# 87
    Dallas, Texas 75246-1613, United States
  • Site Reference ID/Investigator# 1279
    Houston, Texas 77030, United States
  • Site Reference ID/Investigator# 1665
    San Antonio, Texas 78229, United States
  • Site Reference ID/Investigator# 1268
    Tyler, Texas 75703, United States
  • Site Reference ID/Investigator# 2079
    Salt Lake City, Utah 84132, United States
  • Site Reference ID/Investigator# 123
    Norfolk, Virginia 23507, United States
  • Site Reference ID/Investigator# 1653
    Seattle, Washington 98101, United States
  • Site Reference ID/Investigator# 2181
    Graz, 8036, Austria
  • Site Reference ID/Investigator# 2180
    Innsbruck, A-6020, Austria
  • Site Reference ID/Investigator# 2176
    Vienna, 1090, Austria
  • Site Reference ID/Investigator# 2554
    Brussels, 1200, Belgium
  • Site Reference ID/Investigator# 2179
    Edegem, 2650, Belgium
  • Site Reference ID/Investigator# 1629
    Calgary, Alberta T2S 3B3, Canada
  • Site Reference ID/Investigator#1641
    Edmonton, Alberta T5K 1X3, Canada
  • Site Reference ID/Investigator# 104
    Vancouver, British Columbia V5Z 4E8, Canada
  • Site Reference ID/Investigator# 1635
    St. John's, Newfoundland and Labrador A1B 4S8, Canada
  • Site Reference ID/Investigator# 120
    St. John's, Newfoundland and Labrador A1C 2H5, Canada
  • Site Reference ID/Investigator# 94
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Site Reference ID/Investigator# 1640
    Hamilton, Ontario L8N 1V6, Canada
  • Site Reference ID/Investigator# 1636
    London, Ontario N5X 2P1, Canada
  • Site Reference ID/Investigator# 1639
    North Bay, Ontario P1B 3Z7, Canada
  • Site Reference ID/Investigator# 1633
    Toronto, Ontario M5V 2T3, Canada
  • Site Reference ID/Investigator# 1631
    Waterloo, Ontario N2J 1C4, Canada
  • Site Reference ID/Investigator# 103
    Windsor, Ontario N8W 1E6, Canada
  • Site Reference ID/Investigator# 102
    Montreal, Quebec H2K 4L5, Canada
  • Site Reference ID/Investigator# 1637
    Montreal, Quebec H2K 4L5, Canada
  • Site Reference ID/Investigator# 101
    Montreal, Quebec H3H 1V4, Canada
  • Site Reference ID/Investigator# 1647
    Westmount, Quebec H3Z 2S6, Canada
  • Site Reference ID/Investigator# 1802
    Quebec, G1V 4X7, Canada
  • Site Reference ID/Investigator# 2553
    Creteil, 94010, France
  • Site Reference ID/Investigator# 2191
    Nice, 06200, France
  • Site Reference ID/Investigator# 2190
    Paris, Cedex 10, 75475, France
  • Site Reference ID/Investigator# 2189
    Saint Etienne, 42055, France
  • Site Reference ID/Investigator# 2198
    Frankfurt, 60590, Germany
  • Site Reference ID/Investigator# 2543
    Kiel, 24105, Germany
  • Site Reference ID/Investigator# 2188
    Muenster, 48149, Germany
  • Site Reference ID/Investigator# 2187
    Tuebingen, 72076, Germany
  • Site Reference ID/Investigator# 2178
    Gdansk, 80-211, Poland
  • Site Reference ID/Investigator# 2177
    Plock, 09-402, Poland
  • Site Reference ID/Investigator# 2194
    Cagaus, 00725, Puerto Rico
  • Site Reference ID/Investigator# 5507
    Carolina, 00985, Puerto Rico

Showing the first 100 of 104 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb;66(2):241-51. doi: 10.1016/j.jaad.2010.12.005. Epub 2011 Jul 14. PubMed 21752491 ↗
  • Papp K, Crowley J, Ortonne JP, Leu J, Okun M, Gupta SR, Gu Y, Langley RG. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011 Feb;164(2):434-41. doi: 10.1111/j.1365-2133.2010.10139.x. PubMed 21083543 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 20, 2005
Start
May 2004
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Nov 19, 2010
Last update
Apr 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00195676
Lead sponsor
Abbott
First posted
Sep 20, 2005
Start date
May 2004
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Nov 19, 2010
Last update
Apr 13, 2011

Study contacts

Martin Okun, MD, PhD
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion